EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Characterizing the Blood-Stage Antimalarial Activity of Tafenoquine in Healthy Volunteers Experimentally Infected With Plasmodium falciparum

Bridget E Barber iD, Azrin N Abd-Rahman, Rebecca Webster, Adam J Potter, Stacey Llewellyn, Louise Marquart, Nischal Sahai, Indika Leelasena, Geoffrey W Birrell, Michael D Edstein, G Dennis Shanks, David Wesche und 2 weitere

Clinical Infectious Diseases · 08.06.2023 · 76 (11) · 1919-1927

DOI: 10.1093/cid/ciad075 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 16.02.2023. Verfasst von Bridget E Barber und 13 weiteren Autor:innen. Beteiligte Einrichtung: QIMR Berghofer Medical Research Institute, Brisbane, Australia. Hauptthemen laut MEDLINE: Antimalarials, Malaria, Falciparum. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bill and Melinda Gates Foundation, QIMR Berghofer Medical Research Institute, Medicines for Malaria Venture.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The long-acting 8-aminoquinoline tafenoquine may be a good candidate for mass drug administration if it exhibits sufficient blood-stage antimalarial activity at doses low enough to be tolerated by glucose 6-phosphate dehydrogenase (G6PD)–deficient individuals.

Methods

Healthy adults with normal levels of G6PD were inoculated with Plasmodium falciparum 3D7-infected erythrocytes on day 0. Different single oral doses of tafenoquine were administered on day 8. Parasitemia and concentrations of tafenoquine and the 5,6-orthoquinone metabolite in plasma/whole blood/urine were measured and standard safety assessments performed. Curative artemether-lumefantrine therapy was administered if parasite regrowth occurred, or on day 48 ± 2. Outcomes were parasite clearance kinetics, pharmacokinetic and pharmacokinetic/pharmacodynamic (PK/PD) parameters from modelling, and dose simulations in a theoretical endemic population.

Results

Twelve participants were inoculated and administered 200 mg (n = 3), 300 mg (n = 4), 400 mg (n = 2), or 600 mg (n = 3) tafenoquine. The parasite clearance half-life with 400 mg or 600 mg (5.4 hours and 4.2 hours, respectively) was faster than with 200 mg or 300 mg (11.8 hours and 9.6 hours, respectively). Parasite regrowth occurred after dosing with 200 mg (3/3 participants) and 300 mg (3/4 participants) but not after 400 mg or 600 mg. Simulations using the PK/PD model predicted that 460 mg and 540 mg would clear parasitaemia by a factor of 106 and 109, respectively, in a 60-kg adult.

Conclusions

Although a single dose of tafenoquine exhibits potent P. falciparum blood-stage antimalarial activity, the estimated doses to effectively clear asexual parasitemia will require prior screening to exclude G6PD deficiency. Clinical Trials Registration. Australian and New Zealand Clinical Trials Registry (ACTRN12620000995976).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntimalarialsMalaria, FalciparumAdultHumansPlasmodium falciparumHealthy VolunteersParasitemiaArtemetherArtemether, Lumefantrine Drug CombinationAustraliaAminoquinolines

Stichwörter der Autor:innen

Plasmodium falciparumantimalarialblood stagetafenoquine

Substanzen

AntimalarialsArtemetherArtemether, Lumefantrine Drug CombinationtafenoquineAminoquinolines

Autor:innen und Institutionen

  • QIMR Berghofer Medical Research Institute, Brisbane, Australia.
  • University of the Sunshine Coast, Morayfield, Australia.
  • Royal Brisbane and Women's Hospital, Brisbane, Australia.
  • The University of Queensland, Brisbane, Australia.
  • Australian Defence Force Malaria and Infectious Disease Institute, Brisbane, Australia.
  • Certara, Ann Arbor, Michigan, USA.

ORCID-Profile: Bridget E Barber

Förderung

  • Bill and Melinda Gates Foundation
  • QIMR Berghofer Medical Research Institute
  • Medicines for Malaria Venture

Zitieren

APA

Barber, B. E., Abd-Rahman, A. N., Webster, R., Potter, A. J., Llewellyn, S., Marquart, L., Sahai, N., Leelasena, I., Birrell, G. W., Edstein, M. D., Shanks, G. D., Wesche, D., Moehrle, J. J., & McCarthy, J. S. (2023). Characterizing the Blood-Stage Antimalarial Activity of Tafenoquine in Healthy Volunteers Experimentally Infected With Plasmodium falciparum. Clinical Infectious Diseases, 76(11), 1919-1927. https://doi.org/10.1093/cid/ciad075

Vancouver

Barber BE, Abd-Rahman AN, Webster R, Potter AJ, Llewellyn S, Marquart L, et al. Characterizing the Blood-Stage Antimalarial Activity of Tafenoquine in Healthy Volunteers Experimentally Infected With Plasmodium falciparum. Clinical Infectious Diseases. 2023;76(11):1919-1927. doi:10.1093/cid/ciad075

BibTeX
@article{Barber2023,
  author = {Barber, Bridget E and Abd-Rahman, Azrin N and Webster, Rebecca and Potter, Adam J and Llewellyn, Stacey and Marquart, Louise and Sahai, Nischal and Leelasena, Indika and Birrell, Geoffrey W and Edstein, Michael D and Shanks, G Dennis and Wesche, David and Moehrle, Joerg J and McCarthy, James S},
  title = {Characterizing the Blood-Stage Antimalarial Activity of Tafenoquine in Healthy Volunteers Experimentally Infected With Plasmodium falciparum},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  volume = {76},
  number = {11},
  pages = {1919--1927},
  doi = {10.1093/cid/ciad075}
}
Kostenlos starten →